Thermo Fisher to Acquire Sanofi Factory; Amphastar Plans Major HQ Expansion

Thermo Fisher Scientific has agreed to acquire Sanofi's sterile manufacturing facility in Ridgefield, New Jersey, a key site for fill-finish and packaging operations serving both Sanofi and broader pharma/biotech needs1235.

The Ridgefield site employs over 200 people, all of whom will join Thermo Fisher after the deal is finalized, expected in the second half of 2025 pending regulatory approvals135.

Thermo Fisher will continue manufacturing Sanofi’s portfolio of sterile injectable therapies at the Ridgefield plant, while also investing to expand capacity and capabilities for additional clients13.

The acquisition strengthens domestic drug product manufacturing, with the facility integrating into Thermo Fisher’s Laboratory Products and Biopharma Services segment and their U.S. Accelerator™ network35.

Amphastar Pharmaceuticals announced it will quadruple the production capacity at its California headquarters manufacturing site over the next three to five years in response to increasing demand4.

Sources:

1. https://www.pharmajournalist.com/thermo-fisher-and-sanofi-expand-u-s-drug-manufacturing-partnership/

2. https://www.pharmamanufacturing.com/industry-news/news/55303601/thermo-fisher-to-acquire-sanofi-sterile-drug-site-to-expand-us-capacity

3. https://www.genengnews.com/topics/bioprocessing/thermo-fisher-agrees-to-acquire-sanofis-steriles-manufacturing-site/

4. https://www.fiercepharma.com/manufacturing/amphastar-plan-quadruple-its-manufacturing-capacity-headquarters-site-california

5. https://ir.thermofisher.com/investors/news-events/news/news-details/2025/Thermo-Fisher-Scientific-and-Sanofi-Expand-Strategic-Partnership-to-Enable-Additional-U-S--Drug-Product-Manufacturing/default.aspx